The trajectory of Viagra, formerly marketed by copyright, presents a intricate case study for stakeholders considering the drug landscape . Despite its early success and impact of billions in earnings , the intellectual property lapse has opened the door for generic medications, substantially eroding income opportunities. This shift raises doubts a